The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Plexxikon
Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).
 
Charles Peterfy
Consulting or Advisory Role - Abbvie; Novartis; SetPoint Medical
Speakers' Bureau - Amgen
Research Funding - Abbvie (Inst); Centrexion (Inst); Crescendo Bioscience (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Flexion Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivir (Inst); Moximed (Inst); Novartis (Inst); Roche TCRC (Inst); Salix (Inst); Samsung (Inst); Sanofi/Regeneron (Inst); SetPoint Medical (Inst)
 
Xin Ye
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Heather Gelhorn
Research Funding - Evidera (Inst)
 
Rebecca M Speck
Research Funding - Evidera (Inst)
 
Peter J. Countryman
No Relationships to Disclose
 
Vicki Leigh Keedy
Employment - Zimmer BioMet (I)
Consulting or Advisory Role - Janssen Oncology; Karyopharm Therapeutics; Threshold Pharmaceuticals
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); eleison pharmaceuticals (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Janssen (Inst); Lilly (Inst); medpacto (Inst); pfizer (Inst); Plexxikon (Inst); Roche (Inst); Threshold Pharmaceuticals (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Array BioPharma; Five Prime Therapeutics; Sirtex Medical
Speakers' Bureau - Genentech
Research Funding - Biomarin (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech
 
Arun S. Singh
No Relationships to Disclose
 
Bartosz Chmielowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Immunocore; Merck
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Janssen; Merck
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; Capella Therapeutics; Cell Therapeutics; CerRx; McKesson; Medtronic; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Aduro Biotech; Aeglea Biotherapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; ARIAD; ARMO BioSciences; Arvinas; Athenex; Bellicum Pharmaceuticals; BeyondSpring Pharmaceuticals; Bicycle Therapeutics; BiolineRx; Biological Dynamics; Bionomics; Boston Biomedical; Bristol-Myers Squibb; CanBas; Cancer Prevention Pharmaceuticals; Cerulean Pharma; CORRONA; CV6 Therapeutics ; CytomX Therapeutics; Daiichi Sankyo; Deciphera; Defined Health; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; FibroGen; Five Prime Therapeutics; FORMA Therapeutics; Formula Pharmaceuticals; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gilead Sciences; HealthCare Pharmaceuticals; Histogen; Horizon Discovery; Horizon Pharma; HUYA Bioscience International; Idera; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunophotonics; Innate Pharma; Insys Therapeutics; Intezyne Technologies; Janssen Diagnostics; Jounce Therapeutics; Kalos Therapeutics; Kinex; Kura Oncology; L.E.A.F. Pharmaceuticals; Lantern Pharma; Lilly; Lixte Biotechnology; MBC Pharma; Medical Prognosis Institute; miRNA Therapeutics; Novocure; Oncology Venture; Oncolytics; Oncolyze; Pain Therapeutics; Pfizer; Pharmamab; Phosplatin Therapeutics; Progen; Reflexion Medical; RenovoRx; Samus Therapeutics; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sumitomo Dainippon; Sun Biopharma; Superlab Far East; Synergene; Systems Imagination; Tavistock Life Sciences; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trovagene; Ventana Medical Systems; Verily; Vertex; Viamet Pharmaceuticals
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Hani M. Babiker
Consulting or Advisory Role - Celgene; Endocyte
 
Vivek Khemka
Employment - Cancer Treament Centers of America
Consulting or Advisory Role - Axess Oncology
 
Gregory Michael Cote
Consulting or Advisory Role - Advance Medical; InfiniteMD
Research Funding - Agios (Inst); Amgen (Inst); Boston Biomedical (Inst); Epizyme (Inst); Macrogenics (Inst); Otsuka (Inst); PharmaMar (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Pfizer; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Andrew J. Wagner
Consulting or Advisory Role - Lilly
Research Funding - Celldex (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
John H. Healey
No Relationships to Disclose
 
Henry Hsu
Employment - Plexxikon
Leadership - Plexxikon
Consulting or Advisory Role - Plexxikon
 
Paul S. Lin
Employment - Plexxikon
Leadership - Plexxikon
Stock and Other Ownership Interests - Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Plexxikon
 
Sandra Tong
No Relationships to Disclose
 
William D. Tap
Consulting or Advisory Role - Adaptimmune; Daiichi Sankyo; Eisai; EMD Serono; Immune Design; Janssen; Lilly; Novartis; Plexxikon; TRACON Pharma